Recent investigations have converged on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and DA communication. While GIP agonists are widely employed for managing type 2 T2DM, their unexpected consequences on reward circuits, specifically influenced by dopaminergic pathway